By Colin Kellaher
Reneo Pharmaceuticals has agreed to combine with privately held OnKure in an all-stock reverse merger that will create a clinical-stage biopharmaceutical company focused on advancing OnKure's portfolio of precision cancer drugs.
Reneo on Monday said the combined company will have about $120 million of cash resources at closing, including $65 million from a planned private financing, which would provide a runway into the fourth quarter of 2026.
A reverse merger allows a private company to go public by merging with a public one at a lower cost than is involved in traditional initial public offerings.
Reneo, based in Irvine, Calif., said that excluding the financing, its shareholders will own about 31% of the combined company, while OnKure investors will own roughly 69%.
Reneo said the combined company will operate under the name OnKure Therapeutics and trade on the Nasdaq Global Market under the ticker OKUR.
The deal and private financing are slated to close later this year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 13, 2024 08:13 ET (12:13 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.